Monday, February 26, 2024
Cytovation is a clinical-stage oncology biotech focused on the development of CyPep-1, a first-in-class synthetic peptide designed to drive a systemic anti-cancer immune response, with a unique dual mode of action: (1) Selective targeting of the cancer cell plasma membrane releases neoantigens that drive a tumor-specific immune response, (2) inhibition of the beta-catenin oncogenic pathway promotes immune activation and reverses immune exclusion. Building on a successful Ph 1 study demonstrating a favorable safety profile and highly encouraging efficacy signals across solid tumor types, Cytovation is advancing into Ph 2. Initial focus will be on Adrenocortical Carcinoma, a rare b-catenin-driven cancer, which can allow a fast route-to-market, while opening the door to broader b-catenin-driven indications, like HCC and CRC.
CEO/Top Company Official
Lars Prestegarden, MD, PhD
Lead Product in Development
CyPep-1, a first-in-class synthetic peptide designed to drive a systemic anti-cancer immune response, with a dual mode of action: (1) exposure of tumor neoantigens to the immune system, and (2) inhibition of the beta-catenin oncogenic pathway.
Development Phase of Primary Product
Number Of Unlicensed Products